Study Details

General Information

Pfizer DM 2 C3421005

A 16-Week, Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily PF-06882961 Administration in Adults with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin or Diet and Exercise

ProtocolC3421005
IdentifierPO
UID5ef64a5c-3ac8-4418-849b-efea14c07fa0
StatusDone - Archived
Phase2b
CategoryDiabetes Type 2 / Adult
Launch Year2020
NCT Number-
Created2019-04-10 13:39
Last Updated2019-04-10 13:39

Description

No description provided.

Comment

No comment.

Target Dates

NameDateRequired
Enrollment Closed2021-01-21No
Enrollment Open2020-09-25No
First Patient First VisitNo
Site Initiation Mtg.2020-09-24No
PI Meeting StartNo
PI Meeting EndNo
PI Meeting ArrivalNo
PI Meeting DepartureNo
Closeout Date2021-11-17No
Final PatientVisitNo
PreStudy Selection VisitNo
Target Date 12No
Target Date 13No
Target Date 14No

Leadership

RoleStaffLoginRequired
PrincipalCasaclang, CeciliaCCasaclangNo
RecruiterMiss, SalomonSMissNo
CoordinatorDiaz-Chavez, MayraMDiaz-ChavezNo
RegulatoryRamirez, ClaudiaCRamirezNo

Custom Fields

No custom fields.

Sponsor & Organization

SponsorPfizer
DivisionPfizer
TeamPfizer
Managing SiteCatalina Research Institute, LLC
Organization

Contacts

IRB Ref
CROParexel International
CRO Ref
Correspondence0

Opportunity

Probability0
Comment
Status ColorGainsboro
Currency-
Mayra Sibley

2 Hours

Hi there, I'm Jesse and you?
You

3 minutes

My name is Anne Clarc.
Mayra Sibley

40 seconds

Nice to meet you Anne.
How can i help you?